ArticlePakistan journal of medical sciences2025
Helicobacter pylori infection, clarithromycin-resistant genes and CYP2C19 gene polymorphisms in asymptomatic school-age children in Baigou New Town, Baoding City, Hebei Province.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and safety of triple therapy with vonoprazan forWorld journal of gastroenterology · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the prevalence of Helicobacter pylori (Hp) infection, clarithromycin (CAM)-resistant genes and CYP2C19 gene polymorphisms in asymptomatic school-age children in Baigou New Town, Baoding City, Hebei Province, China. Methods: This retrospective study recruited 1,068 primary school students from Baigou New Town, Baoding City, Hebei Province, China, in November 2023 to screen for Hp infection and detect clarithromycin-resistant genes using stool samples. Additionally, blood samples were collected for CYP2C19 gene polymorphism analysis. Results: The stool antigen test for Hp yielded a positive rate of 18.4% (197/1,068). Among the 197 Hp-positive patients, 36.5% were resistant to CAM. The polymorphism analysis revealed that, in the 23S rRNA V region, the overall mutation rate was 62.5% for the A2143G site, 77.7% for T2182C, 50% for A2143G and T2182C, 2.7% for A2142C and 1.3% for A2142G. Moreover, the analysis classified the study participants into three CYP2C19 phenotypes (i.e., extensive, intermediate and poor metabolisers; extensive metabolisers (EM), intermediate metabolisers (IM) and poor metabolisers (PM), respectively), and the prevalence was 45.6%, 44.6% and 9.6% for EM, IM and PM, respectively. Conclusion: The local area showed a high CAM resistance, indicating that CAM is not preferred for Hp eradication. CYP2C19 gene polymorphism analysis revealed that the EM phenotype was highly prevalent. Therefore, a comprehensive analysis of CYP2C19 gene polymorphisms is recommended to identify ideal proton-pump inhibitors for Hp eradication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.